UBS Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,206,681
| Closed | -$250M | – | 10428 |
|
|
2026
Q1 | $250M | Buy |
6,206,681
+2,020,459
| +48% | +$43.5M | 0.04% | 510 |
|
|
2025
Q4 | $105M | Buy |
4,186,222
+756,317
| +22% | +$17.7M | 0.02% | 986 |
|
|
2025
Q3 | $77.6M | Sell |
3,429,905
-1,305,406
| -28% | -$30.4M | 0.01% | 1241 |
|
|
2025
Q2 | $82M | Buy |
4,735,311
+1,463,117
| +45% | +$27.1M | 0.01% | 1116 |
|
|
2025
Q1 | $71.6M | Buy |
3,272,194
+685,455
| +26% | +$18.9M | 0.01% | 1162 |
|
|
2024
Q4 | $82.5M | Buy |
2,586,739
+2,272,055
| +722% | +$68.3M | 0.02% | 1043 |
|
|
2024
Q3 | $9.08M | Buy |
314,684
+42,287
| +16% | +$1.57M | ﹤0.01% | 2462 |
|
|
2024
Q2 | $10.4M | Buy |
272,397
+161,105
| +145% | +$7.3M | ﹤0.01% | 2182 |
|
|
2024
Q1 | $6.54M | Buy |
111,292
+16,258
| +17% | +$1.04M | ﹤0.01% | 2683 |
|
|
2023
Q4 | $5.69M | Buy |
95,034
+91,168
| +2,358% | +$4.62M | ﹤0.01% | 2657 |
|
|
2023
Q3 | $147K | Sell |
3,866
-92,589
| -96% | -$4.07M | ﹤0.01% | 5586 |
|
|
2023
Q2 | $8.79M | Sell |
96,455
-7,909
| -8% | -$682K | ﹤0.01% | 2060 |
|
|
2023
Q1 | $6.88M | Sell |
104,364
-27,533
| -21% | -$1.59M | ﹤0.01% | 2219 |
|
|
2022
Q4 | $6.82M | Buy |
131,897
+117,258
| +801% | +$6.22M | ﹤0.01% | 2208 |
|
|
2022
Q3 | $1M | Sell |
14,639
-57,484
| -80% | -$3.4M | ﹤0.01% | 3751 |
|
|
2022
Q2 | $3.26M | Sell |
72,123
-42,526
| -37% | -$1.94M | ﹤0.01% | 2726 |
|
|
2022
Q1 | $5.83M | Buy |
114,649
+5,262
| +5% | +$232K | ﹤0.01% | 2396 |
|
|
2021
Q4 | $5.17M | Sell |
109,387
-87,495
| -44% | -$3.44M | ﹤0.01% | 2775 |
|
|
2021
Q3 | $6.49M | Buy |
196,882
+140,763
| +251% | +$7.91M | ﹤0.01% | 2413 |
|
|
2021
Q2 | $3.55M | Buy |
56,119
+44,425
| +380% | +$2.29M | ﹤0.01% | 3036 |
|
|
2021
Q1 | $502K | Buy |
11,694
+10,663
| +1,034% | +$505K | ﹤0.01% | 4862 |
|
|
2020
Q4 | $59K | Buy |
1,031
+738
| +252% | +$31.2K | ﹤0.01% | 6034 |
|
|
2020
Q3 | $9K | Sell |
293
-2,527
| -90% | -$75.5K | ﹤0.01% | 6912 |
|
|
2020
Q2 | $92K | Sell |
2,820
-10,118
| -78% | -$325K | ﹤0.01% | 5364 |
|
|
2020
Q1 | $347K | Sell |
12,938
-5,933
| -31% | -$211K | ﹤0.01% | 4289 |
|
|
2019
Q4 | $578K | Sell |
18,871
-11,981
| -39% | -$332K | ﹤0.01% | 4709 |
|
|
2019
Q3 | $743K | Sell |
30,852
-15,674
| -34% | -$431K | ﹤0.01% | 4227 |
|
|
2019
Q2 | $1.18M | Buy |
46,526
+37,175
| +398% | +$756K | ﹤0.01% | 3617 |
|
|
2019
Q1 | $182K | Sell |
9,351
-54,828
| -85% | -$862K | ﹤0.01% | 4657 |
|
|
2018
Q4 | $847K | Buy |
64,179
+38,146
| +147% | +$585K | ﹤0.01% | 3826 |
|
|
2018
Q3 | $463K | Buy |
26,033
+19,544
| +301% | +$361K | ﹤0.01% | 4466 |
|
|
2018
Q2 | $143K | Buy |
6,489
+1,298
| +25% | +$29.8K | ﹤0.01% | 5187 |
|
|
2018
Q1 | $115K | Buy |
5,191
+1,288
| +33% | +$25.3K | ﹤0.01% | 5137 |
|
|
2017
Q4 | $85K | Buy |
+3,903
| New | +$57.5K | ﹤0.01% | 5469 |
|
Other funds holding APLS
UBS Group's APLS Position: Q2 2026 in Review
UBS Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,206,681 shares — an estimated $250M sold.
UBS Group first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $250M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- UBS Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 6,206,681 Apellis Pharmaceuticals shares in Q2 2026, an estimated $250M.
- UBS Group first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- UBS Group's Apellis Pharmaceuticals position peaked at $250M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.